Temporal lobe epilepsy (TLE) is the most frequent drug-resistant epilepsy. It represents approximately two thirds of the intractable seizure population requiring surgical management (
1). Surgical treatment for these patients is typically a safe, effective and well-established option, with a success rate of 70% to 90% (
2).
The best surgical outcomes are obtained when the epileptic zone (EZ) (
3) is accurately localized during the pre-surgical evaluation. The EZ usually includes the ictal-onset zone (IOZ), the cortical region where seizures start and, in a variable and not well-defined degree, the interictal or irritative zone (IZ), the area showing interictal epileptiform discharges (IEDs). The ancillary tests used during the pre-surgical evaluation include (
2,
4) video-electroencephalography (v-EEG), magnetic resonance imaging (MRI), single photon emission-computed tomography (SPECT) and positron emission tomography (PET). When results of the tests are not functionally and anatomically consistent, invasive recordings, such as foramen ovale (FO), subdural or depth electrodes are required (
5). Pharmacological activation inducing or increasing interictal activity is also used as a complementary method, together with v-EEG to improve accuracy in the pre-surgical diagnosis. The tested drugs include: methohexital (
6), clonidine (
7), pentylenetetrazol (
8), thiopental (
9) and opiates (
10). Nevertheless, the results were not specific and adverse effects were poorly tolerated, decreased safety and precluded the use of many drugs. Etomidate is a non-barbiturate imidazole derivative hypnotic agent with a rapid onset, a short duration of action, and minor side effects associated with intravenous perfusion. It acts as a selective modulator of the gaminobutyric acid receptor A (GABA
A). It is shown that etomidate can be safely used to activate epileptogenic activity (
11-
16)
In fact, Pastor et al. (2010) showed that etomidate induced interictal spiking activity ipsilateral to the ictal onset zone (IOZ) and can correctly lateralize 95% of the patients with TLE. Furthermore, as this drug facilitates the reliable identification of the IOZ, it could be used to diagnose patients who do not experience seizures during v-EEG recordings or influence decisions regarding the placement of intracranial electrodes. In a recent work, authors showed that etomidate perfusion induce changes in the underlying epileptic network related to the ones found during spontaneous seizures (
17).
The current paper reviewed the evidence found to date, about the effects of etomidate in the interictal and ictal activities and epileptic network in patients with temporal lobe epilepsy, in an effort to support its potential value as an additional diagnostic tool for the preoperative assessment in patients with drug-resistant epilepsy.